HSR Clearance Clears Key Hurdle for Olin-Huntsman Merger, Shifting Thesis from Standalone Turnaround to Deal Completion

What happened

The announcement that the Hart-Scott-Rodino waiting period has expired removes a major regulatory obstacle to the proposed merger of Olin and Huntsman. This clears the way for the companies to proceed toward closing, assuming shareholder approvals and other customary conditions are satisfied. The news marks a significant shift for Huntsman, which had been evaluated on its standalone prospects in a cyclical downturn with high leverage and persistent losses. With the merger now more likely, the investment case for HUN shareholders hinges on the deal's terms, including the exchange ratio, expected synergies, and integration execution. While the regulatory clearance is positive, the combined entity will still face cyclical demand, high leverage, and execution risks that could affect long-term value.

Implication

Investors should reassess HUN as a merger arbitrage situation, comparing the current share price to the implied deal value based on Olin's share price and the exchange ratio. The expiration of HSR reduces regulatory uncertainty, but the deal still requires shareholder votes and possibly other approvals, so a gap may remain. The combined company's pro forma leverage and earnings power will be critical; both Olin and Huntsman have cyclical exposure and elevated debt, so synergies must be credible to justify the transaction. Historical merger integration in chemicals often encounters challenges, and the timing within a downcycle may delay realization of benefits. Overall, while the deal likely provides an exit for Huntsman shareholders at a premium to the standalone valuation, the premium may be modest given the overvaluation relative to the DCF anchor, and investors should not overlook integration and execution risks.

Thesis delta

The previous thesis viewed Huntsman as a standalone cyclical turnaround with a 'WAIT' rating due to high leverage and lack of margin of safety. The HSR clearance materially changes the investment case to one based on the merger's completion and terms, reducing the relevance of standalone DCF as the primary valuation anchor. The thesis now shifts to assessing the deal economics, including synergies and combined balance sheet, with a neutral-to-positive bias if the exchange ratio offers fair value, but still carrying integration and cyclical risks.